.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Septic myocardial injury represents a critical challenge in emergency and critical care medicine today. This condition occurs when systemic inflammation triggers profound cardiac dysfunction during severe infections. Consequently, clinicians are increasingly exploring adjunctive therapies like Xuebijing (XBJ) to improve patient outcomes. Recent research highlights how XBJ alleviates septic myocardial injury by targeting iron-induced cell death mechanisms.
Specifically, the study utilized LPS-induced models to examine molecular triggers of heart damage. It found that ICAM1 expression rises significantly during sepsis, which subsequently activates Toll-like receptor (TLR) signaling. This activation leads to a surge in inflammatory cytokines and accelerates cardiomyocyte apoptosis. However, XBJ effectively suppresses ICAM1, thereby inhibiting the overactivated TLR pathway. Furthermore, XBJ reduces levels of biomarkers such as cTnI and BNP, which serve as reliable indicators of cardiac stress.
Beyond inflammation, XBJ addresses iron death mediated by proteins like TFR1 and ASCL4. This process, also known as ferroptosis, contributes heavily to myocardial tissue degradation. By restoring glutathione (GSH) levels and decreasing malondialdehyde (MDA), XBJ provides a robust antioxidant effect. Consequently, cardiomyocytes demonstrate improved survival rates even under high-stress conditions. Therefore, XBJ serves as a multi-target agent capable of tackling inflammation and iron-mediated damage simultaneously.
Xuebijing functions by inhibiting inflammatory responses and reducing iron-mediated cell death (ferroptosis) via the ICAM1/TLR signaling pathway.
Research indicates that XBJ treatment can lower levels of cTnI, BNP, and CK-MB, which are key indicators of myocardial damage.
Disclaimer: This content is for informational and educational purposes only. It is not intended to provide medical advice or to be a substitute for professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
New research shows Xuebijing (XBJ) alleviates septic myocardial injury by inhibiting the ICAM1/TLR signaling pathway and reducing iron-mediated cell death....
4 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
